Sunday, December 09, 2018 11:18:59 AM
NWBO investors are being played like a fiddle.AVII77
Aracaris Capital Limited
The Vision Centre
Former Spicers Site Mill Lane Sawston Cambridge
PROPOSED CHANGE OF USE FROM B8 TO B2 USE TO CREATE ADVANCED THERAPY MEDICINE MANUFACTURING FACILITY
TRANSPORT STATEMENT VOLUME 1 of 2 TEXT FIGURES AND TABLES
Technical Report 56000/2 August 2014
Mark Baker
Consulting Limited
Bristol.
3.6 Movement Generation: First Principles
3.6.1 The proposal is a particular specialised type of manufacturing, and hence it is appropriate to consider the assessment of movement generation based on a first principles assessment.
3.6.2 The site is proposed to be operated by a contract manufacturer of medicines, but whilst most conventional drugs are manufactured from their constituent chemicals, the medicines produced are manufactured from human cells, and typically from the patients themselves. The medicines produced are “cutting edge”, and are part of a new class of medicines called Advanced Therapy Medicines.
3.6.3 Every medicine produced at the site will originate from human donor cells, and / or tissues. These will derive either from the patient, or a close relative, but there may be some from a bank of cells made specifically for one type of product including for example stem cell bank from donated umbilical cord blood. Another starting material is organs from the NHS Blood and Transplant Service that is unsuitable for routine transplantation but can be used as a “scaffold” for product development. Such products will be harvested across the UK, and transported to Sawston by specialised courier service.
3.6.4 The work that will be involved in the production of such medicines is undertaken on a small scale across the UK in major hospital, but this facilities would be the first “large scale” manufacturing facility. That said the work at the site is largely similar to that seen at Blood Transfusion Centres with the predominant traffic generation being by car for staff, and any professional visitors, and by the unit’s own vehicles for goods in and out for the most part.
3.6.5 It is anticipated that when fully operational, and in full occupation the site will employ the following levels of staff by skill type, and shift:
i) Manufacturing staff would work on two shifts from Monday to Saturday 07.30 – 16.30 25 staff 15.00 – 23.00 25 staff
ii) Warehouse staff would also work on two shifts from Monday to Saturday 07.30 – 16.30 4 staff 15.00 – 23.00 4 staff
iii) Site security staff on three shifts 07.30 – 16.30 1 staff 15.00 – 23.00 1 staff
iv) 5 scientists for product development on Monday to Friday 09.00 – 17.30
v) 5 office / support staff on Monday to Friday 09.00 – 17.30
3.6.6 Table 3 shows the arrival / departure profiles based on a first principles assessment. The arrival / departure profile assumes that staff will arrive and depart within the quarter of an hour before and after their shift start respectively. As a “worst case” assessment, the profiles assume the following modal split:
Car 94%
Cycle 4%
Walk including public transport 2%
These values are from the Sawston Business Park TA. There were no values provided for by public transport access which are taken as being included within the walk percentages.
3.6.7 The profile also indicates an assessment of parking accumulation which indicates that between 14.45 and 16.45 that there may be a need to accommodate the parking demand of two shifts of 65 vehicles in total. The overall car parking provision including the main car park would be adequate to accommodate the demand by staff, and visitors.
3.6.8 In addition to the staff movements, there are likely to be regular, and irregular goods vehicle movements as follows:
Delivery and pick up 20 per day by transit sized vehicle
Delivery by box van 12 per week
Cryogenic delivery trucks 2 per week (once every 3 days)
Domestic refuse removal 1 per week
Clinical waste removal by box van 3 per week
3.7 Traffic Distribution
3.7.1 The vehicular traffic distribution used for testing purposes if appropriate will be identical to that of the TA prepared for the Sawston Business Park planning application for cars, and goods vehicles as follows:
Cars HGVs
a) To / from Whittlesford Road 20% 0%
b) To / from A1301 then
To / from the north 20% 33%
To / from Sawston 20% 0%
To / from south 40% 67%
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
